Aripiprazole structure
|
Common Name | Aripiprazole | ||
---|---|---|---|---|
CAS Number | 129722-12-9 | Molecular Weight | 448.385 | |
Density | 1.3±0.1 g/cm3 | Boiling Point | 646.2±55.0 °C at 760 mmHg | |
Molecular Formula | C23H27Cl2N3O2 | Melting Point | 139°C | |
MSDS | Chinese USA | Flash Point | 344.6±31.5 °C | |
Symbol |
GHS06, GHS08 |
Signal Word | Danger |
Use of AripiprazoleAripiprazole(Abilify) is a human 5-HT1A receptor partial agonist with a Ki of 4.2 nM. IC50 Value: 4.2 nM(Ki)Target: 5-HT ReceptorAripiprazole is an atypical antipsychotic medication used for the treatment of schizophrenia. It has also recently received FDA approval for the treatment of acute manic and mixed episodes associated with bipolar disorder. Aripiprazole appears to mediate its antipsychotic effects primarily by partial agonism at the D2 receptor. In addition to partial agonist activity at the D2 receptor, aripiprazole is also a partial agonist at the 5-HT1A receptor, and like the other atypical antipsychotics, aripiprazole displays an antagonist profile at the 5-HT2A receptor. Aripiprazole has moderate affinity for histamine and alpha adrenergic receptors, and no appreciable affinity for cholinergic muscarinic receptors. |
Name | aripiprazole |
---|---|
Synonym | More Synonyms |
Description | Aripiprazole(Abilify) is a human 5-HT1A receptor partial agonist with a Ki of 4.2 nM. IC50 Value: 4.2 nM(Ki)Target: 5-HT ReceptorAripiprazole is an atypical antipsychotic medication used for the treatment of schizophrenia. It has also recently received FDA approval for the treatment of acute manic and mixed episodes associated with bipolar disorder. Aripiprazole appears to mediate its antipsychotic effects primarily by partial agonism at the D2 receptor. In addition to partial agonist activity at the D2 receptor, aripiprazole is also a partial agonist at the 5-HT1A receptor, and like the other atypical antipsychotics, aripiprazole displays an antagonist profile at the 5-HT2A receptor. Aripiprazole has moderate affinity for histamine and alpha adrenergic receptors, and no appreciable affinity for cholinergic muscarinic receptors. |
---|---|
Related Catalog | |
References |
Density | 1.3±0.1 g/cm3 |
---|---|
Boiling Point | 646.2±55.0 °C at 760 mmHg |
Melting Point | 139°C |
Molecular Formula | C23H27Cl2N3O2 |
Molecular Weight | 448.385 |
Flash Point | 344.6±31.5 °C |
Exact Mass | 447.148041 |
PSA | 44.81000 |
LogP | 5.59 |
Vapour Pressure | 0.0±1.9 mmHg at 25°C |
Index of Refraction | 1.593 |
Storage condition | -20°C Freezer |
Symbol |
GHS06, GHS08 |
---|---|
Signal Word | Danger |
Hazard Statements | H301 + H311 + H331-H370 |
Precautionary Statements | Missing Phrase - N15.00950417-P261-P280-P302 + P352 + P312-P304 + P340 + P312-P403 + P233 |
Hazard Codes | F,Xn |
Risk Phrases | 11-20/21/22-36 |
Safety Phrases | S26-S36 |
RIDADR | UN 1993C 3 / PGIII |
WGK Germany | 3 |
HS Code | 2933790090 |
Precursor 6 | |
---|---|
DownStream 2 | |
HS Code | 2933790090 |
---|---|
Summary | 2933790090. other lactams. VAT:17.0%. Tax rebate rate:9.0%. . MFN tariff:9.0%. General tariff:20.0% |
Blonanserin extensively occupies rat dopamine D3 receptors at antipsychotic dose range.
J. Pharmacol. Sci. 127(3) , 326-31, (2015) Antagonism of the dopamine D3 receptor has been hypothesized to be beneficial for schizophrenia cognitive deficits, negative symptoms and extrapyramidal symptoms. However, recent animal and human stud... |
|
In vivo pharmacological characterization of TAK-063, a potent and selective phosphodiesterase 10A inhibitor with antipsychotic-like activity in rodents.
J. Pharmacol. Exp. Ther. 352(3) , 471-9, (2015) Phosphodiesterase 10A (PDE10A) is a cAMP/cGMP phosphodiesterase highly expressed in medium spiny neurons (MSNs) in the striatum. We evaluated the in vivo pharmacological profile of a potent and select... |
|
The use of dried blood spots for quantification of 15 antipsychotics and 7 metabolites with ultra-high performance liquid chromatography - tandem mass spectrometry.
Drug Test. Anal. 7 , 502-11, (2015) Therapeutic drug monitoring of antipsychotics is important in optimizing individual therapy. In psychiatric populations, classical venous blood sampling is experienced as frightening. Interest in alte... |
7-[4-[4-(2,3-Dichlorophenyl)-1-piperazinyl]butoxy]-3,4-dihydro-2(1H)-quinolinone |
2(1H)-quinolinone, 7-4-4-(2,3-dichlorophenyl)-1-piperazinylbutoxy-3,4-dihydro- |
Abilify |
2(1H)-Quinolinone, 7-[4-[4-(2,3-dichlorophenyl)-1-piperazinyl]butoxy]-3,4-dihydro- |
7-{4-[4-(2,3-Dichlorophenyl)-1-piperazinyl]butoxy}-3,4-dihydro-2(1H)-quinolinone |
7-{4-[4-(2,3-dichlorophenyl)piperazin-1-yl]butoxy}-3,4-dihydroquinolin-2(1H)-one |
UNII-82VFR53I78 |
7-{4-4-(2,3-dichlorophenyl)piperazin-1-ylbutoxy}-3,4-dihydroquinolin-2(1H)-one |
Aripiprazole |
7-[4-[4-(2,3-dichlorophenyl)piperazin-1-yl]butoxy]-3,4-dihydro-1H-quinolin-2-one |
EINECS 200-835-2 |
MFCD00892072 |